SinoMab BioScience Limited (03681)

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

SinoMab BioScience Limited (03681)

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid

CS Hotline: +852 3018 4526

Trading days: 24 hours | Non-trading days: 9:00-18:00

Headquarters

Sheung Wan

Address: Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong

North District

Address: 1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong

Email: cs@usmart.hk

WhatsApp: +852 5989 2641

uSMART Branches(Causeway Bay coming soon)

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907) holding Type 1 Licence for Dealing in Securities, Type 4 Licence for Advising on Securities, Type 6 Licence for Advising on Corporate Finance, and Type 9 Licence for Asset Management.

Market News

SinoMab BioScience Limited (03681)

Services

About Us

Agreement Statement